TriangleFOR PATIENTS · SOURCE READING
Low-risk Gestational Trophoblastic Neoplasia
Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2022 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: Treatment Options for Gestational Trophoblastic Disease / Gestational Trophoblastic Neoplasia
Treatment of low-risk gestational trophoblastic neoplasia (GTN) (invasive mole or choriocarcinoma) may include the following:
Source links and citations
Chemotherapy with one or more anticancer drugs. Treatment is given until the beta human chorionic gonadotropin (beta-hCG) level is normal for at least 3 weeks after treatment ends.
Source links and citations
If the level of beta-hCG in the blood does not return to normal or the tumor spreads to distant parts of the body, chemotherapy regimens used for high-risk metastatic GTN are given.
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice